Inteferons pen the JAK-STAT pathway

Seminars in Cell and Developmental Biology

Volumn 19, Issue 4, 2008, Pages 311-318

  Schindler, Christian ^a   Plumlee, Courtney ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Cytokines; Interferons (IFNs); JAKs; STATs and signal transduction

Indexed keywords

INTERFERON; JANUS KINASE; PHOSPHATASE; STAT PROTEIN; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; STAT5 PROTEIN; STAT6 PROTEIN; TRANSCRIPTION FACTOR;

ENZYME ACTIVATION; ENZYME ACTIVITY; NUCLEAR EXPORT SIGNAL; NUCLEAR IMPORT; PROTEIN ANALYSIS; PROTEIN MODIFICATION; REVIEW;

EID: 52949111844     PISSN: 10849521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcdb.2008.08.010     Document Type: Review

References (158)

1. Isaacs A., and Lindenmann J. Virus interference. I. The interferon. Proc Roy Soc Lond B Biol Sci 147 (1957) 258-267
2. Pestka S. The human interferon alpha species and receptors. Biopolymers 55 (2000) 254-287
3. Levy D., Larner A., Chaudhuri A., Babiss L.E., and Darnell Jr. J.E. Interferon-stimulated transcription: isolation of an inducible gene and identification of its regulatory region. Proc Natl Acad Sci USA 83 (1986) 8929-8933
4. Reich N., Evans B., Levy D., Fahey D., Knight Jr. E., and Darnell Jr. J.E. Interferon-induced transcription of a gene encoding a 15-kDa protein depends on an upstream enhancer element. Proc Natl Acad Sci USA 84 (1987) 6394-6398
5. Fu X.-Y., Schindler C., Improta T., Aebersold R., and Darnell J.E. The proteins of ISGF-3, the IFN-α induced transcription activator, define a new family of signal transducers. Proc Natl Acad Sci USA 89 (1992) 7840-7843
6. Kessler D.S., Levy D.E., and Darnell Jr. J.E. Two interferon-induced nuclear factors bind a single promoter element in interferon-stimulated genes. Proc Natl Acad Sci USA 85 (1988) 8521-8525
7. Schindler C., Fu X.Y., Improta T., Aebersold R., and Darnell Jr. J.E. Proteins of transcription factor ISGF-3: one gene encodes the 91- and 84-kDa ISGF-3 proteins that are activated by interferon alpha. Proc Natl Acad Sci USA 89 (1992) 7836-7839
8. Schindler C., Shuai K., Prezioso V.R., and Darnell Jr. J.E. Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science 257 (1992) 809-813
9. Shuai K., Schindler C., Prezioso V., and Darnell J.E. Activation of transcription by IFN-γ: tyrosine phosphorylation of a 91-kDa DNA binding protein. Science 258 (1992) 1808-1812
10. Velazquez L., Fellous M., Stark G.R., and Pellegrini S. A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell 70 (1992) 313-322
11. Levy D.E., and Darnell Jr. J.E. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3 (2002) 651-662
12. Decker T., Muller M., and Stockinger S. The yin and yang of type I interferon activity in bacterial infection. Nat Rev Immunol 5 (2005) 675-687
13. O'Shea J.J., Gadina M., and Schreiber R.D. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 109 Suppl (2002) S121-S131
14. Alexander W.S., and Hilton D.J. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol 22 (2004) 503-529
15. Levy D., Reich N., Kessler D., Pine R., and Darnell Jr. J.E. Transcriptional regulation of interferon-stimulated genes: a DNA response element and induced proteins that recognize it. Cold Spring Harb Symp Quant Biol 53 Pt 2 (1988) 799-802
16. Fu X.Y., Kessler D.S., Veals S.A., Levy D.E., and Darnell Jr. J.E. ISGF3, the transcriptional activator induced by interferon alpha, consists of multiple interacting polypeptide chains. Proc Natl Acad Sci USA 87 (1990) 8555-8559
17. Levy D.E., Kessler D.S., Pine R., and Darnell Jr. J.E. Cytoplasmic activation of ISGF3, the positive regulator of interferon-alpha-stimulated transcription, reconstituted in vitro. Genes Dev 3 (1989) 1362-1371
18. Veals S.A., Schindler C., Leonard D., Fu X.Y., Aebersold R., Darnell Jr. J.E., et al. Subunit of an alpha-interferon-responsive transcription factor is related to interferon regulatory factor and Myb families of DNA-binding proteins. Mol Cell Biol 12 (1992) 3315-3324
19. Shuai K., Schindler C., Prezioso V.R., and Darnell Jr. J.E. Activation of transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA binding protein. Science 258 (1992) 1808-1812
20. Lew D.J., Decker T., Strehlow I., and Darnell J.E. Overlapping elements in the guanylate-binding protein gene promoter mediate transcriptional induction by alpha and gamma interferons. Mol Cell Biol 11 (1991) 182-191
21. Eilers A., Seegert D., Schindler C., Baccarini M., and Decker T. The response of gamma interferon activation factor is under developmental control in cells of the macrophage lineage. Mol Cell Biol 13 (1993) 3245-3254
22. Kanno Y., Kozak C.A., Schindler C., Driggers P.H., Ennist D.L., Gleason S.L., et al. The genomic structure of the murine ICSBP gene reveals the presence of the gamma interferon-responsive element, to which an ISGF3 alpha subunit (or similar) molecule binds. Mol Cell Biol 13 (1993) 3951-3963
23. Pearse R.N., Feinman R., Shuai K., Darnell Jr. J.E., and Ravetch J.V. Interferon gamma-induced transcription of the high-affinity Fc receptor for IgG requires assembly of a complex that includes the 91-kDa subunit of transcription factor ISGF3. Proc Natl Acad Sci USA 90 (1993) 4314-4318
24. Becker S., Groner B., and Muller C.W. Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature 394 (1998) 145-151
25. Chen X., Vinkemeier U., Zhao Y., Jeruzalmi D., Darnell Jr. J.E., and Kuriyan J. Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell 93 (1998) 827-839
26. Gupta P., Blazar B.R., Gupta K., and Verfaillie C.M. Human CD34(+) bone marrow cells regulate stromal production of interleukin-6 and granulocyte colony-stimulating factor and increase the colony-stimulating activity of stroma. Blood 91 (1998) 3724-3733
27. Shuai K., Horvath C.M., Huang L.H., Qureshi S.A., Cowburn D., and Darnell Jr. J.E. Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell 76 (1994) 821-828
28. Firmbach-Kraft I., Byers M., Shows T., Dalla-Favera R., and Krolewski J.J. tyk2, prototype of a novel class of non-receptor tyrosine kinase genes. Oncogene 5 (1990) 1329-1336
29. Wilks A.F., Harpur A.G., Kurban R.R., Ralph S.J., Zurcher G., and Ziemiecki A. Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol Cell Biol 11 (1991) 2057-2065
30. Silvennoinen O., Ihle J.N., Schlessinger J., and Levy D.E. Interferon-induced nuclear signalling by Jak protein tyrosine kinases. Nature 366 (1993) 583-585
31. Watling D., Guschin D., Muller M., Silvennoinen O., Witthuhn B.A., Quelle F.W., et al. Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway. Nature 366 (1993) 166-170
32. Argetsinger L.S., Campbell G.S., Yang X., Witthuhn B.A., Silvennoinen O., Ihle J.N., et al. Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell 74 (1993) 237-244
33. Müller M., Briscoe J., Laxton C., Guschin D., Ziemiecki A., Silvennoinen O., et al. The protein tyrosine kinase JAK1 complements defects in interferon- alpha/beta and -gamma signal transduction. Nature 366 (1993) 129-135
34. Bonni A., Frank D.A., Schindler C., and Greenberg M.E. Characterization of a pathway for ciliary neurotrophic factor signaling to the nucleus. Science 262 (1993) 1575-1579
35. Akira S., Nishio Y., Inoue M., Wang X.J., Wei S., Matsusaka T., et al. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 77 (1994) 63-71
36. Yamamoto K., Quelle F.W., Thierfelder W.E., Kreider B.L., Gilbert D.J., Jenkins N.A., et al. Stat4, a novel gamma interferon activation site-binding protein expressed in early myeloid differentiation. Mol Cell Biol 14 (1994) 4342-4349
37. Zhong Z., Wen Z., and Darnell Jr. J.E. Stat3 and Stat4: members of the family of signal transducers and activators of transcription. Proc Natl Acad Sci USA 91 (1994) 4806-4810
38. Schindler C., Kashleva H., Pernis A., Pine R., and Rothman P. STF-IL4: a novel IL-4 induced signal transducing factor. EMBO J 13 (1994) 1350-1356
39. Hou J., Schindler U., Henzel W.J., Ho T.C., Brasseur M., and McKnight S.L. An interleukin-4-induced transcription factor: IL-4 Stat. Science 265 (1994) 1701-1706
40. Azam M., Erdjument-Bromage H., Kreider B.L., Xia M., Quelle F., Basu R., et al. Interleukin-3 signals through multiple isoforms of Stat5. EMBO J 14 (1995) 1402-1411
41. Mui A.L., Wakao H., O'Farrell A.M., Harada N., and Miyajima A. Interleukin-3, granulocyte-macrophage colony stimulating factor and interleukin-5 transduce signals through two STAT5 homologs. EMBO J 14 (1995) 1166-1175
42. Wakao H., Gouilleux F., and Groner B. Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response. EMBO J 13 (1994) 2182-2191
43. Kawamura M., McVicar D.W., Johnston J.A., Blake T.B., Chen Y.Q., Lal B.K., et al. Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. Proc Natl Acad Sci USA 91 (1994) 6374-6378
44. Kotenko S.V., Gallagher G., Baurin V.V., Lewis-Antes A., Shen M., Shah N.K., et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4 (2003) 69-77
45. Sheppard P., Kindsvogel W., Xu W., Henderson K., Schlutsmeyer S., Whitmore T.E., et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4 (2003) 63-68
46. Schindler C., Levy D.E., and Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem 282 (2007) 20059-20063
47. Murray P.J. The JAK-STAT signaling pathway: input and output integration. J Immunol 178 (2007) 2623-2629
48. Rodig S.J., Meraz M.A., White J.M., Lampe P.A., Riley J.K., Arthur C.D., et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 93 (1998) 373-383
49. Neubauer H., Cumano A., Mueller M., Wu H., Huffstadt U., and Pfeffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93 (1998) 397-409
50. Parganas E., Wang D., Stravopodis D., Topham D.J., Marine J.C., Teglund S., et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93 (1998) 385-395
51. Tefferi A. JAK and MPL mutations in myeloid malignancies. Leuk Lymphoma 49 (2008) 388-397
52. Nosaka T., vanDeursen J.M., Tripp R.A., Thierfelder W.E., Witthuhn B.A., McMickle A.P., et al. Defective lymphoid development in mice lacking Jak3. Science 270 (1995) 800-802
53. Park S.Y., Saijo K., Takahashi T., Osawa M., Arase H., Hirayama N., et al. Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity 3 (1995) 771-782
54. Thomis D.C., Gurniak C.B., Tivol E., Sharpe A.H., and Berg L.J. Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science 270 (1995) 794-797
55. Seto Y., Nakajima H., Suto A., Shimoda K., Saito Y., Nakayama K.I., et al. Enhanced Th2 cell-mediated allergic inflammation in Tyk2-deficient mice. J Immunol 170 (2003) 1077-1083
56. Karaghiosoff M., Neubauer H., Lassnig C., Kovarik P., Schindler H., Pircher H., et al. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 13 (2000) 549-560
57. Shimoda K., Kato K., Aoki K., Matsuda T., Miyamoto A., Shibamori M., et al. Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity 13 (2000) 561-571
58. Minegishi Y., Saito M., Morio T., Watanabe K., Agematsu K., Tsuchiya S., et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25 (2006) 745-755
59. Karaghiosoff M., Steinborn R., Kovarik P., Kriegshauser G., Baccarini M., Donabauer B., et al. Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock. Nat Immunol 4 (2003) 471-477
60. Kisseleva T., Bhattacharya S., Braunstein J., and Schindler C.W. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285 (2002) 1-24
61. Miyoshi K., Cui Y., Riedlinger G., Lehoczky J., Zon L., Oka T., et al. Structure of the mouse stat 3/5 locus: evolution from drosophila to zebrafish to mouse. Genomics 71 (2001) 150-155
62. Neculai D., Neculai A.M., Verrier S., Straub K., Klumpp K., Pfitzner E., et al. Structure of the unphosphorylated STAT5a dimer. J Biol Chem 280 (2005) 40782-40787
63. Mao X., Ren Z., Parker G.N., Sondermann H., Pastorello M.A., Wang W., et al. Structural bases of unphosphorylated STAT1 association and receptor binding. Mol Cell 17 (2005) 761-771
64. Mertens C., Zhong M., Krishnaraj R., Zou W., Chen X., and Darnell Jr. J.E. Dephosphorylation of phosphotyrosine on STAT1 dimers requires extensive spatial reorientation of the monomers facilitated by the N-terminal domain. Genes Dev 20 (2006) 3372-3381
65. Zhong M., Henriksen M.A., Takeuchi K., Schaefer O., Liu B., ten Hoeve J., et al. Implications of an antiparallel dimeric structure of nonphosphorylated STAT1 for the activation-inactivation cycle. Proc Natl Acad Sci USA 102 (2005) 3966-3971
66. Braunstein J., Brutsaert S., Olson R., and Schindler C. STATs dimerize in the absence of phosphorylation. J Biol Chem 278 (2003) 34133-34140
67. McBride K.M., and Reich N.C. The ins and outs of STAT1 nuclear transport. Sci STKE 2003 (2003) RE13
68. Meyer T., Marg A., Lemke P., Wiesner B., and Vinkemeier U. DNA binding controls inactivation and nuclear accumulation of the transcription factor Stat1. Genes Dev 17 (2003) 1992-2005
69. Bhattacharya S., and Schindler C. Regulation of Stat3 nuclear export. J Clin Invest 111 (2003) 553-559
70. Park C., Lecomte M.J., and Schindler C. Murine Stat2 is uncharacteristically divergent. Nucleic Acids Res 27 (1999) 4191-4199
71. Decker T., Müller M., and Kovarik P. Regulation of Stats by posttranslational modification. In: Seghal P.B., Hirano T., and Levy D.E. (Eds). Signal transducers and activators of transcription (Stats): activation and biology (2003), Kluwer Academic
72. Ramsauer K., Farlik M., Zupkovitz G., Seiser C., Kroger A., Hauser H., et al. Distinct modes of action applied by transcription factors STAT1 and IRF1 to initiate transcription of the IFN-{gamma}-inducible gbp2 gene. Proc Natl Acad Sci USA 104 (2007) 2849-2854
73. Litterst C.M., and Pfitzner E. An LXXLL motif in the transactivation domain of STAT6 mediates recruitment of NCoA-1/SRC-1. J Biol Chem 277 (2002) 36052-36060
74. Giraud S., Bienvenu F., Avril S., Gascan H., Heery D.M., and Coqueret O. Functional interaction of STAT3 transcription factor with the coactivator NcoA/SRC1a. J Biol Chem 277 (2002) 8004-8011
75. Paulson M., Press C., Smith E., Tanese N., and Levy D.E. IFN-Stimulated transcription through a TBP-free acetyltransferase complex escapes viral shutoff. Nat Cell Biol 4 (2002) 140-147
76. Letimier F.A., Passini N., Gasparian S., Bianchi E., and Rogge L. Chromatin remodeling by the SWI/SNF-like BAF complex and STAT4 activation synergistically induce IL-12Rbeta2 expression during human Th1 cell differentiation. EMBO J 26 (2007) 1292-1302
77. Pattenden S.G., Klose R., Karaskov E., and Bremner R. Interferon-gamma-induced chromatin remodeling at the CIITA locus is BRG1 dependent. EMBO J 21 (2002) 1978-1986
78. Liu H., Kang H., Liu R., Chen X., and Zhao K. Maximal induction of a subset of interferon target genes requires the chromatin-remodeling activity of the BAF complex. Mol Cell Biol 22 (2002) 6471-6479
79. Huang M., Qian F., Hu Y., Ang C., Li Z., and Wen Z. Chromatin-remodelling factor BRG1 selectively activates a subset of interferon-alpha-inducible genes. Nat Cell Biol 4 (2002) 774-781
80. Nusinzon I., and Horvath C.M. Unexpected roles for deacetylation in interferon- and cytokine-induced transcription. J Interferon Cytokine Res 25 (2005) 745-748
81. Rascle A., Johnston J.A., and Amati B. Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5. Mol Cell Biol 23 (2003) 4162-4173
82. Wang D., Moriggl R., Stravopodis D., Carpino N., Marine J.C., Teglund S., et al. A small amphipathic alpha-helical region is required for transcriptional activities and proteasome-dependent turnover of the tyrosine-phosphorylated Stat5. EMBO J 19 (2000) 392-399
83. Tanaka T., Soriano M.A., and Grusby M.J. SLIM is a nuclear ubiquitin E3 ligase that negatively regulates STAT signaling. Immunity 22 (2005) 729-736
84. Maritano D., Sugrue M.L., Tininini S., Dewilde S., Strobl B., Fu X., et al. The STAT3 isoforms alpha and beta have unique and specific functions. Nat Immunol 5 (2004) 401-409
85. Ivanov V.N., Bhoumik A., Krasilnikov M., Raz R., Owen-Schaub L.B., Levy D., et al. Cooperation between STAT3 and c-jun suppresses Fas transcription. Mol Cell 7 (2001) 517-528
86. Durbin J.E., Hackenmiller R., Simon M.C., and Levy D.E. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84 (1996) 443-450
87. Meraz M.A., White J.M., Sheehan K.C., Bach E.A., Rodig S.J., Dighe A.S., et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84 (1996) 431-442
88. Chapgier A., Boisson-Dupuis S., Jouanguy E., Vogt G., Feinberg J., Prochnicka-Chalufour A., et al. Novel STAT1 alleles in otherwise healthy patients with mycobacterial disease. PLoS Genet 2 (2006) e131
89. Jouanguy E., Lamhamedi-Cherradi S., Lammas D., Dorman S.E., Fondaneche M.C., Dupuis S., et al. A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. Nat Genet 21 (1999) 370-378
90. Costa-Pereira A.P., Tininini S., Strobl B., Alonzi T., Schlaak J.F., Is'harc H., et al. Mutational switch of an IL-6 response to an interferon-gamma -like response. Proc Natl Acad Sci USA 99 (2002) 8043-8047
91. Muller M., Laxton C., Briscoe J., Schindler C., Improta T., Darnell Jr. J.E., et al. Complementation of a mutant cell line: central role of the 91 kDa polypeptide of ISGF3 in the interferon-alpha and -gamma signal transduction pathways. EMBO J 12 (1993) 4221-4228
92. Improta T., Schindler C., Horvath C.M., Kerr I.M., Stark G.R., and Darnell Jr. J.E. Transcription factor ISGF-3 formation requires phosphorylated Stat91 protein, but Stat113 protein is phosphorylated independently of Stat91 protein. Proc Natl Acad Sci USA 91 (1994) 4776-4780
93. Qureshi S.A., Leung S., Kerr I.M., Stark G.R., and Darnell Jr. J.E. Function of Stat2 protein in transcriptional activation by alpha interferon. Mol Cell Biol 16 (1996) 288-293
94. Pedersen I.M., Cheng G., Wieland S., Volinia S., Croce C.M., Chisari F.V., et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 449 (2007) 919-922
95. Park C., Li S., Cha E., and Schindler C. Immune response in Stat2 knockout mice. Immunity 13 (2000) 795-804
96. Hahm B., Trifilo M.J., Zuniga E.I., and Oldstone M.B. Viruses evade the immune system through type I interferon-mediated STAT2-dependent, but STAT1-independent, signaling. Immunity 22 (2005) 247-257
97. Zhao W., Cha E.N., Lee C., Park C.Y., and Schindler C. Stat2-dependent regulation of MHC class II expression. J Immunol 179 (2007) 463-471
98. Akira S., Nishio Y., Inoue M., Wang X.-J., Wei S., Matsusaka T., et al. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 77 (1994) 63-71
99. Zhang X., Wrzeszczynska M.H., Horvath C.M., and Darnell Jr. J.E. Interacting regions in Stat3 and c-Jun that participate in cooperative transcriptional activation. Mol Cell Biol 19 (1999) 7138-7146
100. Jankovic D., and Trinchieri G. IL-10 or not IL-10: that is the question. Nat Immunol 8 (2007) 1281-1283
101. Takeda K., Noguchi K., Shi W., Tanaka T., Matsumoto M., Yoshida N., et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci USA 94 (1997) 3801-3804
102. Yoshimatsu T., Kawaguchi D., Oishi K., Takeda K., Akira S., Masuyama N., et al. Non-cell-autonomous action of STAT3 in maintenance of neural precursor cells in the mouse neocortex. Development 133 (2006) 2553-2563
103. Hokuto I., Ikegami M., Yoshida M., Takeda K., Akira S., Perl A.K., et al. Stat-3 is required for pulmonary homeostasis during hyperoxia. J Clin Invest 113 (2004) 28-37
104. Gao Q., Wolfgang M.J., Neschen S., Morino K., Horvath T.L., Shulman G.I., et al. Disruption of neural signal transducer and activator of transcription 3 causes obesity, diabetes, infertility, and thermal dysregulation. Proc Natl Acad Sci USA 101 (2004) 4661-4666
105. Alonzi T., Maritano D., Gorgoni B., Rizzuto G., Libert C., and Poli V. Essential role of STAT3 in the control of the acute-phase response as revealed by inducible gene inactivation [correction of activation] in the liver. Mol Cell Biol 21 (2001) 1621-1632
106. Levy D.E., and Lee C.K. What does Stat3 do?. J Clin Invest 109 (2002) 1143-1148
107. Lee C.K., Raz R., Gimeno R., Gertner R., Wistinghausen B., Takeshita K., et al. STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. Immunity 17 (2002) 63-72
108. Chapman R.S., Lourenco P.C., Tonner E., Flint D.J., Selbert S., Takeda K., et al. Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev 13 (1999) 2604-2616
109. Levy D.E., and Loomis C.A. STAT3 signaling and the hyper-IgE syndrome. N Engl J Med 357 (2007) 1655-1658
110. de la Iglesia N., Konopka G., Puram S.V., Chan J.A., Bachoo R.M., You M.J., et al. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev (2008)
111. Inghirami G., Chiarle R., Simmons W.J., Piva R., Schlessinger K., and Levy D.E. New and old functions of STAT3: a pivotal target for individualized treatment of cancer. Cell Cycle 4 (2005) 1131-1133
112. Chen Z., Laurence A., and O'Shea J.J. Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation. Semin Immunol 19 (2007) 400-408
113. Mathur A.N., Chang H.C., Zisoulis D.G., Stritesky G.L., Yu Q., O'Malley J.T., et al. Stat3 and Stat4 direct development of IL-17-secreting Th cells. J Immunol 178 (2007) 4901-4907
114. Owaki T., Asakawa M., Morishima N., Mizoguchi I., Fukai F., Takeda K., et al. STAT3 is indispensable to IL-27-mediated cell proliferation but not to IL-27-induced Th1 differentiation and suppression of proinflammatory cytokine production. J Immunol 180 (2008) 2903-2911
115. Yu H., Kortylewski M., and Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7 (2007) 41-51
116. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G.C., and Albanese Darnell J.E. Stat3 as an oncogene. Cell 98 (1999) 295-303
117. Naugler W.E., and Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 14 (2008) 109-119
118. Copeland N.G., Gilbert D.J., Schindler C., Zhong Z., Wen Z., Darnell Jr. J.E., et al. Distribution of the mammalian Stat gene family in mouse chromosomes. Genomics 29 (1995) 225-228
119. Hunter C.A. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 5 (2005) 521-531
120. Zhong Z., Wen Z., and Darnell Jr. J.E. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264 (1994) 95-98
121. Wurster A.L., Tanaka T., and Grusby M.J. The biology of Stat4 and Stat6. Oncogene 19 (2000) 2577-2584
122. Thierfelder W.E., van Deursen J.M., Yamamoto K., Tripp R.A., Sarawar S.R., Carson R.T., et al. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature 382 (1996) 171-174
123. Kaplan M.H., Sun Y.L., Hoey T., and Grusby M.J. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature 382 (1996) 174-177
124. Morinobu A., Gadina M., Strober W., Visconti R., Fornace A., Montagna C., et al. STAT4 serine phosphorylation is critical for IL-12-induced IFN-gamma production but not for cell proliferation. Proc Natl Acad Sci USA 99 (2002) 12281-12286
125. Teglund S., McKay C., Schuetz E., van Deursen J.M., Stravopodis D., Wang D., et al. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 93 (1998) 841-850
126. Udy G.B., Towers R.P., Snell R.G., Wilkins R.J., Park S.H., Ram P.A., et al. Requirement of Stat5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci USA 94 (1997) 7239-7244
127. Cui Y., Riedlinger G., Miyoshi K., Tang W., Li C., Deng C.X., et al. Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol Cell Biol 24 (2004) 8037-8047
128. Yao Z., Cui Y., Watford W.T., Bream J.H., Yamaoka K., Hissong B.D., et al. Stat5a/b are essential for normal lymphoid development and differentiation. Proc Natl Acad Sci USA 103 (2006) 1000-1005
129. Hebenstreit D., Wirnsberger G., Horejs-Hoeck J., and Duschl A. Signaling mechanisms, interaction partners, and target genes of STAT6. Cytokine Growth Factor Rev 17 (2006) 173-188
130. Takeda K., Tanaka T., Shi W., Matsumoto M., Minami M., Kashiwamura S., et al. Essential role of Stat6 in IL-4 signalling. Nature 380 (1996) 627-630
131. Shimoda K., van Deursen J., Sangster M.Y., Sarawar S.R., Carson R.T., Tripp R.A., et al. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 380 (1996) 630-633
132. Kaplan M.H., Schindler U., Smiley S.T., and Grusby M.J. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 4 (1996) 313-319
133. Shuai K. Modulation of STAT signaling by STAT-interacting proteins. Oncogene 19 (2000) 2638-2644
134. Zhu M., John S., Berg M., and Leonard W.J. Functional association of Nmi with Stat5 and Stat1 in IL-2- and IFNgamma-mediated signaling. Cell 96 (1999) 121-130
135. Kramer O.H., Baus D., Knauer S.K., Stein S., Jager E., Stauber R.H., et al. Acetylation of Stat1 modulates NF-kappaB activity. Genes Dev 20 (2006) 473-485
136. Nadiminty N., Lou W., Lee S.O., Lin X., Trump D.L., and Gao A.C. Stat3 activation of NF-{kappa}B p100 processing involves CBP/p300-mediated acetylation. Proc Natl Acad Sci USA 103 (2006) 7264-7269
137. Yuan Z.L., Guan Y.J., Chatterjee D., and Chin Y.E. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 307 (2005) 269-273
138. Gewinner C., Hart G., Zachara N., Cole R., Beisenherz-Huss C., and Groner B. The coactivator of transcription CREB-binding protein interacts preferentially with the glycosylated form of Stat5. J Biol Chem 279 (2004) 3563-3572
139. Song L., Bhattacharya S., Yunus A.A., Lima C.D., and Schindler C. Stat1 and SUMO modification. Blood 108 (2006) 3237-3244
140. Komyod W., Bauer U.M., Heinrich P.C., Haan S., and Behrmann I. Are STATS arginine-methylated?. J Biol Chem 280 (2005) 21700-21705
141. Meissner T., Krause E., Lodige I., and Vinkemeier U. Arginine methylation of STAT1: a reassessment. Cell (2004) 119; 587-9; discussion 589-90
142. Varinou L., Ramsauer K., Karaghiosoff M., Kolbe T., Pfeffer K., Muller M., et al. Phosphorylation of the Stat1 transactivation domain is required for full-fledged IFN-gamma-dependent innate immunity. Immunity 19 (2003) 793-802
143. Shen Y., Schlessinger K., Zhu X., Meffre E., Quimby F., Levy D.E., et al. Essential role of STAT3 in postnatal survival and growth revealed by mice lacking STAT3 serine 727 phosphorylation. Mol Cell Biol 24 (2004) 407-419
144. Kojima H., Sasaki T., Ishitani T., Iemura S., Zhao H., Kaneko S., et al. STAT3 regulates Nemo-like kinase by mediating its interaction with IL-6-stimulated TGFbeta-activated kinase 1 for STAT3 Ser-727 phosphorylation. Proc Natl Acad Sci USA 102 (2005) 4524-4529
145. Tenoever B.R., Ng S.L., Chua M.A., McWhirter S.M., Garcia-Sastre A., and Maniatis T. Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity. Science 315 (2007) 1274-1278
146. Mustelin T., Vang T., and Bottini N. Protein tyrosine phosphatases and the immune response. Nat Rev Immunol 5 (2005) 43-57
147. Nakahira M., Tanaka T., Robson B.E., Mizgerd J.P., and Grusby M.J. Regulation of signal transducer and activator of transcription signaling by the tyrosine phosphatase PTP-BL. Immunity 26 (2007) 163-176
148. Irie-Sasaki J., Sasaki T., Matsumoto W., Opavsky A., Cheng M., Welstead G., et al. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature 409 (2001) 349-354
149. Haque S.J., Harbor P., Tabrizi M., Yi T., and Williams B.R. Protein-tyrosine phosphatase Shp-1 is a negative regulator of IL-4- and IL-13-dependent signal transduction. J Biol Chem 273 (1998) 33893-33896
150. Aoki N., and Matsuda T. A cytosolic protein tyrosine phosphatase PTP1B specifically dephosphorylates and deactivates prolactin-activated STAT5a and STAT5b. J Biol Chem (2000)
151. Klingmueller U., Lorenz U., Cantley L.C., Neel B.G., and Lodish H.F. Specefic recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of Jak2 and termination of proliferative signals. Cell 80 (1995) 729-738
152. Vinkemeier U. Getting the message across, STAT! Design principles of a molecular signaling circuit. J Cell Biol 167 (2004) 197-201
153. ten Hoeve J., de Jesus Ibarra-Sanchez M., Fu Y., Zhu W., Tremblay M., David M., et al. Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol Cell Biol 22 (2002) 5662-5668
154. Croker B.A., Kiu H., and Nicholson S.E. SOCS regulation of the JAK/STAT signalling pathway. Semin Cell Dev Biol 19 (2008) 414-422
155. Müller P., Boutros M., and Zeidler M.P. Identification of JAK/STAT pathway regulators-insights from RNAi screens. Semin Cell Dev Biol 19 (2008) 360-369
156. Groner B., Lucks P., and Borghouts C. The function of Stat3 in tumor cells and their microenvironment. Semin Cell Dev Biol 19 (2008) 341-350
157. Wilks A.F. The JAK kinases: not just another kinase drug discovery target. Semin Cell Dev Biol 19 (2008) 319-328
158. Vainchenker W., Dusa A., and Constantinescu S.N. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol 19 (2008) 385-393